NYSEARCA: XBI · IEX Real-Time Price · USD
-0.74 (-1.00%)
Sep 22, 2023, 4:00 PM EDT - Market closed
Assets $6.04B
Expense Ratio 0.35%
PE Ratio n/a
Shares Out n/a
Dividend (ttm) $0.00
Dividend Yield 0.00%
Ex-Dividend Date Jun 20, 2023
Payout Ratio n/a
1-Year Return -6.57%
Volume 9,650,909
Open 73.95
Previous Close 73.70
Day's Range 72.81 - 74.22
52-Week Low 72.44
52-Week High 92.60
Beta n/a
Holdings 138
Inception Date Jan 31, 2006

About XBI

Fund Home Page

The SPDR S&P BIOTECH ETF (XBI) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund tracks an equal-weighted index of US biotechnology stocks. XBI was launched on Jan 31, 2006 and is issued by State Street.

Asset Class Equity
Category Health
Region North America
Stock Exchange NYSEARCA
Ticker Symbol XBI
Index Tracked S&P Biotechnology Select Industry

Top 10 Holdings

13.35% of assets
Name Symbol Weight
Apellis Pharmaceuticals, Inc. APLS 1.45%
Amgen Inc. AMGN 1.33%
Halozyme Therapeutics, Inc. HALO 1.33%
Neurocrine Biosciences, Inc. NBIX 1.33%
Vertex Pharmaceuticals Incorporated VRTX 1.33%
Ionis Pharmaceuticals, Inc. IONS 1.32%
Alkermes plc ALKS 1.32%
AbbVie Inc. ABBV 1.32%
Mirati Therapeutics, Inc. MRTX 1.31%
Seagen Inc. SGEN 1.30%
View More Holdings


Ex-Dividend Amount Pay Date
2023-06-20 $0.00262 2023-06-23
2021-03-22 $0.040 2021-03-25
2020-12-21 $0.176 2020-12-24
2020-09-21 $0.08897 2020-09-24
2020-06-22 $0.01676 2020-06-25
2019-12-20 $0.00086 2019-12-26
Full Dividend History


Best Healthcare ETFs to Buy Now

The best healthcare ETFs patch investors into an area of the market that offers both defensive properties and long-term growth.

4 weeks ago - Kiplinger

ETF flows point to ‘skittish' investors as it's ‘a little unwieldy out there' after Fed rate hikes

Hello! In this week's ETF Wrap, I caught up with The ETF Store's Nate Geraci and State Street's Matthew Bartolini on flows as investors worry about a potential recession and try to discern the Fed's n...

5 months ago - Market Watch

VettaFi Voices On: Smart Beta and Equal-Weight ETFs

This week, the VettaFi Voices gather around the water cooler and talk smart beta and equal weight ETFs.

5 months ago - ETF Trends

Biotech ETFs' Performance Deserves A Look

Biotech comes with a great many positive externalities for society, and can be a big positive for portfolios right now.

Other symbols: ARKGSBIO
5 months ago - ETF Trends

How to Tell Biotech's Likely Winners From Losers

A discerning approach is warranted even as Merck lifts the sector with a deal for a company without any approved products.

5 months ago - WSJ

Final Trades: XBI, BXP, SPY & MRK

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

Other symbols: BXPMRKSPY
5 months ago - CNBC Television

The FDA Is Resuming Drug Lab Inspections in China. These Biotechs Could Benefit.

China's pandemic-era travel restrictions paused approvals on some new drugs. The end of Zero Covid means the pipeline will reopen.

5 months ago - Barrons

Final Trades: Biotech, Defense, Thermo Fisher & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other symbols: TMOITAPFG
5 months ago - CNBC Television

Passive Funds' Ownership of US Stocks Soars

Share prices appear unaffected as passive ETF and mutual fund stakes hit 19%, analysis says.

Other symbols: IJSKBWYSDY
6 months ago - ETFcom

Regional banks pace decliners, as biotech deals lift Seagen and Provention Bio

Here are some of the biggest movers on Monday with banks firmly in focus after federal regulators stepped into protect deposits at fallen bank SVB.

Other symbols: IBBKRE
6 months ago - Market Watch

SVB fallout: The impacts on the biotech sector

CNBC's Meg Tirrell reports on how the SVB fallout could impact biotech investors.

Other symbols: SIVBIBB
6 months ago - CNBC Television

Biotech ETF nears a six-month low

Shares of the SPDR S&P Biotech ETF XBI tumbled toward a six-month low last week, closing at $75.66 on Friday, over concerns about biotech exposure to Silicon Valley Bank, which is owned by SVB Financi...

6 months ago - Market Watch

The Recent Bullish Trend in IBB, XBI Looks Shaky

Rising interest rates taking steam from rally that powered in IBB and XBI. 

Other symbols: IBB
7 months ago - ETFcom

Analysis: Biotech IPOs to bloom with spotlight on startups with human trial data

Initial public offerings by small private biotech companies are poised to stage a comeback later in 2023 as the pace of interest rate hikes slows, but tougher economic conditions will make investors m...

Other symbols: IBB
7 months ago - Reuters

There's a crop of great biotech companies ready to be acquired, says MPM's Christiana Bardon

Dr. Christiana Bardon, co-managing partner of MPM's BioImpact Capital, joins 'The Exchange' to discuss tailwinds in the pharmaceutical and biotech sector, innovation in obesity drugs, and acquisition ...

Other symbols: IBB
8 months ago - CNBC Television

Final Trades: Stryker, DaVita, Biotech and more

The "Halftime Report" traders give their top picks to watch for the second half.

Other symbols: DVASYKUUP
8 months ago - CNBC Television

Why Biotech Is Poised for a Recovery This Year

Pharma and biotech stocks moved in opposite directions last year, but fortunes are shifting.

Other symbols: IBB
8 months ago - WSJ

Will 2023 be the year that pharma M&A makes a comeback?

A handful of acquisitions this week point to a more deal-friendly year for biopharma and biotech companies, though none has generated the kind of excitement seen in years past.

Other symbols: XPH
9 months ago - Market Watch

Expect heavy market selling early next year, says Worth Charting's Carter Worth

Carter Worth, Worth Charting CEO, joins 'The Exchange' to give the technical take on Eli Lilly and XBI.

Other symbols: LLY
10 months ago - CNBC Television

Final Trades: ServiceNow, Devon Energy S&P Biotech & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other symbols: DVNNOWWRB
11 months ago - CNBC Television

XBI vs IBB: what's a better way to play the biotech space?

Biotech will continue to outperform the benchmark since the U.S. economy is currently in late-cycle expansion, says Bryn Talkington. She's a Managing Partner at Requisite Capital Management.

Other symbols: IBB
11 months ago - Invezz

Requisite's Bryn Talkington discusses whys she liked XBI over IBB in biotech

Bryn Talkington, Requisite Capital, joins 'Closing Bell: Overtime' to discuss the biotech sector.

11 months ago - CNBC Television

Janney Montgomery Scott's Mark Luschini urges near-term caution

Mark Luschini, Janney Montgomery Scott chief investment strategist, joins 'Power Lunch' to discuss September's Fed minutes, cautious sectors to invest in, and forces influencing defensive stock prices...

Other symbols: XLEXLFXLKXLU
1 year ago - CNBC Television

Life sciences is undervalued right now, says JMP Securities Mark Lehmann

JMP Securities CEO Mark Lehmann joins 'Closing Bell: Overtime' to discuss why he likes health care stocks as the place to be right now.

Other symbols: CFLTCYTKKRTX
1 year ago - CNBC Television

White House unveils $2 billion biotech spending plan ahead of industry summit

The White House released new details on Wednesday on how it plans to invest more than $2 billion in the U.S. biotechnology sector as it hosts a meeting of government leaders to discuss the emerging in...

Other symbols: IBB
1 year ago - Reuters